Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: #1 is the Amylin pathway In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Cagrilintide More Biotechnology 99.9% Purity COA Testing Report Mazdutide Cagrilintide Retatrutide Lyophilized Powder CAS 2381089 83 2 Weight Loss Peptide Research Reagents Ochi Biotech Co., Limited. GLP 1 based therapies for diabetes, obesity and beyond Nature Reviews Drug Discovery